tbuckley/cabot-search huggingface dataset:
FIRST SERIAL 12- AND 24-MONTH OPTICAL COHERENCE TOMOGRAPHY ASSESSMENT OF STEMI PATIENTS AFTER THE GENERATION OF ABSORB BIORESORBABLE VASCULAR SCAFFOLD IMPLANTATION
Authors: Lukasz Koltowski, Janusz Kochman, Mariusz Tomaniak, Arkadiusz Pietrasik, Klaudia Proniewska, Jacek Jakala, Adam Rdzanek, Krzysztof Filipiak, Grzegorz Opolski
Journal: Journal of the American College of Cardiology (2017)
PERIOPERATIVE ADMINISTRATION OF AMIODARONE OR BETA BLOCKERS IN CARDIAC SURGERY: WHICH IS MORE EFFECTIVE IN REDUCING POSTOPERATIVE ATRIAL FIBRILLATION?
Authors: Irene Kirolos, Ouassim Derbal, Rahul Gadde, Danny Yakoub, Carlos Alfonso, Sandra Chaparro, Tomas Salerno, Mauricio Cohen
Journal: Journal of the American College of Cardiology (2017)
LONGITUDINAL CHANGE IN SOLUBLE ST2 VERSUS B-TYPE NATRIURETIC PEPTIDE IN PREDICTING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ASYMPTOMATIC PATIENTS IN THE COMMUNITY
Authors: Isaac Tea, Chris Watson, Eoin O'Connell, Nadezhda Glezeva, Stephanie James, Liam Shiels, Joe Gallagher, James Snider, James Januzzi, Mark Ledwidge, Kenneth McDonald
Journal: Journal of the American College of Cardiology (2017)
Hemoglobin Levels Prior to Blood Transfusions in Oncology Patients Receiving Chemotherapy and Erythropoiesis-Stimulating Agents (ESAs): Observational Data from the DOSE Registry.
Authors: Kay M. Larholt, Tanya Burton, Chris L. Pashos, Brahim K. Bookhart, Catherine Tak Piech, Scott R. McKenzie
Journal: Blood (2007)
IKZF1 Status As an Independent Prognostic Marker in Adult Common B-Cell Acute Lymphoblastic Leukemia
Authors: Qiumei Yao, Kaiyan Liu, Bing Jiang, Yanrong Liu, Qian Jiang, Hao Jiang, Xiaohui Zhang, Shanshan Chen, Xiaojun Huang, Lanping Xu, Guorui Ruan
Journal: Blood (2014)
Monitoring of circulating tumor DNA in metastatic triple-negative breast cancer patients undergoing chemotherapy.
Authors: Jordan Madic, Anna Kiialainen, Francois-Clement Bidard, Fabian Birzele, Guillemette Ramey, Emilie Vinolo, Quentin Leroy, Thomas Rio-Frio, Virginie Bernard, Alban Lermine, Inga Clausen, Nicolas Giroud, Roland Schmucki, Carsten Horn, Olivia Spleiss, Olivier Lantz, Marc-Henri Stern, Jean-Yves Pierga, Martin Weisser, Ronald Lebofsky
Journal: Journal of Clinical Oncology (2014)

e22056 Background: Triple negative breast cancer (TNBC) is associated with aggressive histological features, high relapse rates, and poor overall survival. To improve the management of TNBC patients, there is an unmet need to develop noninvasive biomarkers to monitor treatment efficacy. TP53 mutations are clinically relevant in TNBC since they present in 60-88% of TNBC cases. Thus, circulating cell free tumor DNA (ctDNA) identified by TP53 mutations could serve as a “liquid biopsy” for TNBC tumors. In this study we measured the mutant TP53 fraction in ctDNA of metastatic TNBC patients by next generation sequencing (NGS) and compared our results to Circulating Tumor Cell (CTC) numbers. Methods: 36 women with metastatic TNBC and receiving a new line of systemic therapy were enrolled in this study. DNAs from 36 solid tumors and 56 plasma samples were extracted and amplified using a panel of target specific primers covering all the exons of TP53 and sequenced as described by the TAMSeq protocol. This method uses a microfluidic chip, the Access Array by Fluidigm, to perform PCR enrichment and Illumina bi-directional sequencing. CTC were enumerated by CellSearch technique. Results: Performance status, elevated LDH and CTC≥5/7.5 ml, were significant prognostic factors for overall survival. TP53mutations were identified in 27 (87%) of 31 solid tumor samples. Five FFPE tumor samples were not analyzable due to the fixation process. The same mutation was identified in the ctDNA of 22 (81%) matched plasma samples and the mutant allele contributed to 2-70% total circulating DNA. A decrease of mutant DNA percentage was observed in a second plasma sample during treatment in 8 (66%) of 12 patients. CTCs were ≥5/7.5 ml at baseline in the blood of 16 (50%) of the 32 patients analyzed and their numbers were not correlated with ctDNA concentration levels. Conclusions: ctDNA TP53 analysis by NGS represents a promising approach to assess treatment efficacy in TNBC. In addition, this method could be used when the primary tumor is not available and undetermined mutations need to be identified from a patient’s plasma DNA.
Current Interventional and Surgical Management of Congenital Heart Disease
Authors: Kimberly A. Holst, Sameh M. Said, Timothy J. Nelson, Bryan C. Cannon, Joseph A. Dearani
Journal: Circulation Research (2017)

Successful outcome in the care of patients with congenital heart disease depends on a comprehensive multidisciplinary team. Surgery is offered for almost every heart defect, despite complexity. Early mortality for cardiac surgery in the neonatal period is ≈10% and beyond infancy is <5%, with 90% to 95% of patients surviving with a good quality of life into the adult years. Advances in imaging have facilitated accurate diagnosis and planning of interventions and surgical procedures. Similarly, advances in the perioperative medical management of patients, particularly with intensive care, has also contributed to improving outcomes. Arrhythmias and heart failure are the most common late complications for the majority of defects, and reoperation for valvar problems is common. Lifelong surveillance for monitoring of recurrent or residual structural heart defects, as well as periodic assessment of cardiac function and arrhythmia monitoring, is essential for all patients. The field of congenital heart surgery is poised to incorporate new innovations such as bioengineered cells and scaffolds that will iteratively move toward bioengineered patches, conduits, valves, and even whole organs.
Loss of Sema4D Signaling in Platelets Impairs the Formation and Stability of Arterial Thrombi In Vivo and Reduces Myocardial Infarct Size.
Authors: Li Zhu, Timothy J. Stalker, Tao Wang, Hong Jiang, Atushi Kumanogoh, Hitoshi Kikutani, Peter Gruber, Lawrence F. Brass
Journal: Blood (2007)
Retrospective analysis of dose intensity, toxicity, and clinical outcomes in 5-fluorouracil (5FU)-based regimens in adjuvant treatment of colon cancer.
Authors: Jonathan Loree, Karen E. Mulder, Sunita Ghosh, Jennifer L. Spratlin
Journal: Journal of Clinical Oncology (2013)

e14575 Background: Adjuvant colon cancer treatment relies on 5FU containing regimens as either an IV formulation or as the oral pro-drug, capecitabine, combined with oxaliplatin (FOLFOX6 and CAPOX). We performed a retrospective chart review comparing average relative dose intensity (ARDI), overall survival (OS), disease free survival (DFS), and toxicity profiles of these two regimens. Methods: 233 patients between January 1, 2006 and December 31, 2011 received chemotherapy combining either FOLFOX6 (n= 128) or CAPOX (n=105) in Edmonton, Alberta. ARDI was compared by calculating a percent of target dose achieved in the average cycle for each patient. Data on OS, DFS, baseline demographics, and toxicities were gathered. Survival data was plotted using the Kaplan-Meier method and compared using the log-rank test. Variable comparisons were performed with the Student’s t-test or the Fisher’s Exact test. Follow up was complete until November 1, 2012. Results: Oxaliplatin ARDI was significantly lower in those treated with CAPOX compared to FOLFOX6 (80.72% vs 87.11%, p=0.0033), as was the 5-FU component (87.10% vs 93.60%, p&lt;0.0001). More patients treated with CAPOX had dose limiting toxicities (84.76% vs 73.40%, p=0.039), and there were significantly more Grade 2 and higher toxicities in those on CAPOX (p&lt;0.0001). A similar percentage of goal number of cycles was achieved between CAPOX and FOLFOX6 (87.38% vs 91.80%, p=0.13) and similar neuropathy was noted between groups. Survival analysis demonstrated similar OS and trends towards improved DFS with CAPOX (1 year – 89.55% vs 83.20%, 3 year – 67.13% vs 58.01%, p=0.051). Stage specific analysis showed stage III patients had improved DFS with CAPOX (1 year – 93.36% vs 86.69%, 3 year- 71.58% vs 68.10%, p=0.042) and trends towards improved OS with CAPOX (1 year – 100% vs 95.56%, 3 year – 95.08% vs 80.17%, p=0.16). The groups had similar age, gender, tumor size, and node status, while ECOG was slightly higher with FOLFOX6 (0.589 vs 0.419, p=0.0315). Conclusions: While patients on CAPOX had significantly lower doses of oxaliplatin and the 5-FU component of their treatment they appear to have improved outcomes compared to FOLFOX6.
MELODY-1: A PILOT STUDY OF MACITENTAN IN PULMONARY HYPERTENSION DUE TO LEFT VENTRICULAR DYSFUNCTION
Authors: Jean-Luc Vachiery, Marion Delcroix, Hikmet Al-Hiti, Michela Efficace, Martin Hutyra, Gabriela Lack, Kelly Papadakis, Lewis Rubin
Journal: Journal of the American College of Cardiology (2017)
CLINICAL BURDEN AND COST ANALYSIS OF PULMONARY HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A CROSS SECTIONAL STUDY FROM THE NATIONAL INPATIENT SAMPLE
Authors: Parasuram Krishnamoorthy, Akshaya Gopalakrishnan, Pradhum Ram, Jalaj Garg, Nainesh Patel, Janani Rangaswami, Aman Amanullah
Journal: Journal of the American College of Cardiology (2017)
Recursive partitioning for new classification of patients with esophageal cancer treated by chemoradiotherapy.
Authors: Motoo Nomura, Kohei Shitara, Takeshi Kodaira, Chihiro Kondoh, Daisuke Takahari, Takashi Ura, Hiroyuki Kojima, Minoru Kamata, Kei Muro, Satoshi Sawada
Journal: Journal of Clinical Oncology (2012)

e14500 Background: The 7 th edition of the American Joint Committee on Cancerstaging system does not include lymph node size in the guidelines for staging patients with esophageal cancer. The objectives of this study were to determine the prognostic impact of the largest lymph node diameter (ND) on survival and to develop and validate a new staging system for patients with esophageal squamous cell cancer who were treated with definitive chemoradiotherapy (CRT). Methods: Information on 402 patients with esophageal cancer undergoing CRT at 2 institutions was reviewed. Univariate and multivariate analyses of data from 1 institution were used to assess the impact of clinical factors on survival, and recursive partitioning analysis was performed to develop the new staging classification. To assess its clinical utility, the new classification was validated using data from the second institution. Results: According to RPA, ND stages were best when classified as ND0 (the absence of lymph node metastases), ND1 (&lt; 2.8 cm), and ND2 (≥ 2.8 cm). By multivariate analysis, gender, T, N, and ND stages were independently and significantly associated with survival (p&lt;0.05). The resulting new staging classification showed the following: T1-2ND0 as Group I; T3-4ND0 or T1-2ND1 as Group II; T3-4ND1 as Group III; and TanyND2 as Group IV. The 4 new stages led to good separation of survival curves in both the developmental and validation datasets (p&lt;0.05). Conclusions: Our results showed that lymph node size is a strong independent prognostic factor and that the new staging system, which incorporated lymph node size, provided good prognostic power and discriminated effectively for patients with esophageal cancer undergoing CRT.
酸化ストレス応答アポトーシス誘導蛋白質(ORAIP)の中和は心筋虚血/再潅流障害を著しく減弱する
Authors: Seko Yoshinori, Yao Takako, Fukuda Shuichi, Fujimura Tsutomu, Okumura Ko, Murayama Kimie
Journal: Circulation (2010)
Comparison of S-1 and cisplatin combination versus S-1 adjuvant chemotherapy for advanced gastric cancer.
Authors: Hyo Song Kim, Hei-Cheul Jeung, Minkyu Jung, Hye Ryun Kim, Ji Yeong Ahn, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha
Journal: Journal of Clinical Oncology (2012)

e14652 Background: Adjuvant chemotherapy demonstrated the efficacy for stage II-III gastric cancer patients in the ACT-GC and CLASSIC trial. However, in the subgroup analysis, stage III patients receiving S-1 monotherapy didn’t report survival benefit unlike the capecitabine/oxaliplatin combination regimen in CLASSIC trial. With the assumption that doublet adjuvant chemotherapy may be more effective for advanced stages of patients, we compared the efficacy of S-1/cisplatin (SP) and S-1 adjuvant chemotherapy. Methods: After curative D2 resection, 274 patients were treated with S-1 monotherapy (98 patients, 80 mg/m 2 for 4 weeks, every 6 weeks) or S-1 plus cisplatin (176 patients, S-1 80 mg/m 2 day 1-14 and cisplatin 60 mg/m 2 day 1, every 3 weeks). Treatment was continued for 12 months in S-1 arm and 6 months in SP arm or until unacceptable toxic effects or disease progression. Results: A total of 65 (66.3%) patients in SP and 118 (67%) in S-1 group completed all the treatment. The relative dose intensity of S-1 was 82% for S-1 and 88% for SP group, respectively. During the early times after the operation, more patients in SP group completed adjuvant treatment. More patients in SP discontinued treatment during the 1st cycle (12.5% S-1 vs 8.5 % SP group) and this trend was consisted thereafter. The progression free survival (PFS) was not reached for both groups. For the stage III patients, 2 year PFS was better for SP group (89%) than S-1 group (80.8%). Among the 23 recurrence, S-1 group (19.8%) demonstrated more frequent recurrence than SP group (12%). In terms of tolerance, hematologic toxicities was more frequent in SP group, therefore, 21% of SP group and 3.4% of S-1 monotherapy had grade 3-4 neutropenia. However, for the non-hematologic toxicity, grade 3-4 anorexia was similar and grade 3-4 stomatitis was more common in S-1 group (2.8% vs 7%) Conclusions: S-1 plus cisplatin adjuvant chemotherapy is effective and tolerable. For the high risk patients, considering favorable compliance and slightly better efficacy, combination treatment may be a good therapeutic option. Further studies for optimal drugs and schedule are warranted.
RATES OF ORAL ANTICOAGULANT USE, WHILE IMPROVING OVER TIME, REMAIN LOW AMONG HOSPITALIZED PATIENTS WITH ATRIAL FIBRILLATION
Authors: Sean Pokorney, Christopher Granger, Kevin Anstrom, Eva Kline-Rogers, Mark Alberts, Gerald Naccarelli, Peter Berger, John A. House, Ujjwala Vijapurkar, Jennifer Davidson, Bimal Shah, Elaine Hylek
Journal: Journal of the American College of Cardiology (2017)
Survival impact of different clinical characteristics of 108 cases of recurrent/metastatic salivary gland malignancies (RMSGM) treated with first line chemotherapy (CT).
Authors: Mario Airoldi, Massimiliano Garzaro, Manuela Ceccarelli, Fulvia Pedani, Luca Raimondo, Claudia Bartoli, Elisa Bellini, Gianluca Fora, Chiara Monagheddu, Giancarlo Pecorari
Journal: Journal of Clinical Oncology (2015)

e17059 Background: The role of CT for RMSGM is palliative only. In this abstract we report multivariate analysis of clinical characteristcs impact on survival. Methods: We enrolled 108 pts. Five pts received cisplatin (DDP) 100 mg/sm d1,q 3wks; 8 pts doxorubicin 75 mg/sm d1, q 3wks; 30 pts vinorelbine (VNB) 30 mg/sm d.1,8, q 3wks; 9 pts DDP+ epirubicin 60 mg/sm + 5-FU 600 mg/sm d.1, q 3wks; 42 pts DDP 80 mg/sm d.1 +VNB 25 mg/sm d.1,8, q 3wks and 14 pts carboplatin AUC 5.5. + paclitaxel 175 mg/sm d.1, q 3wks. Results: Pts characteristics were as follows: 64 males (59%) and 44 females (41%); median age: 57 yrs (20-74); 42 pts (39%) had ECOG PS 0 (47%) and 66 PS1-2 (61%); histology: adenocarcinoma (AC) 32 (30%), adenoid cystic ca. (ACC) 59 (55%), undifferentiated ca. (UC) 12 pts (11%) and malignant mixed tumor (MMT) 5 (4%); site of disease: local 41 (38%) , mts + local 29 (27%), mts only 38 (35%). Responses: 3 CR , 24 PR, 36 NC and 45 PD; clinical benefit: PolyCT vs Mono CT : 63% vs 51% ; DDP based vs NoDDP (64% vs 47%). Median TTP was 3.25 m and OS was 8.33 months. Conclusions: PS and histology had a profound impact on survival ; even if polyCT and DDP-based CT had significant better response rates these results don't impact on survival. Crude and adjusted hazards ratios for mortality. Variables HR IC 95% P value HR IC 95% P value Platinum-based agents No 1 - 1 - Yes 0.96 0.65- 1.43 0.84 1.17 0.75 - 1.84 0.49 Performance status 0 1 - 1 1-2 2.54 1.68 -3.83 <0.01 2.81 1.78 -4.44 <0.01 Histology Adenocarcinoma 1 - 1 - Adenoid cystic carcinoma 1.30 0.84 -2.01 0.24 1.66 0.98 - 2.8 0.06 Undifferentiated carcinoma 3.77 1.88 - 7.58 <0.01 3.23 1.49 - 6.97 <0.01 Malignant mixed 4.26 1.60 - 11.38 <0.01 6.99 2.38- 20.49 <0.01 Metastasis Absent 1 - 1 - Present 1.41 0.95- 2.10 0.09 0.9 0.52 - 1.54 0.7
Autologous tumor cell vaccination with PF-3512676 (CPG 7909) and GM-CSF followed by subcutaneous PF-3512676 and IFN-alpha for patients with metastatic renal cell carcinoma
Authors: A. J. Van Den Eertwegh, R. J. Lensen, R. J. Scheper, G. Giaccone, C. J. Meijer, H. J. Bontkes, T. D. Gruijl, E. Hooijberg
Journal: Journal of Clinical Oncology (2006)

2530 Background: Metastatic renal cell carcinoma (RCC) has a poor prognosis with a 5-year survival of less than 10%. Non-specific immunotherapy, e.g. IL-2 and IFN-α achieves responses in 10–30% of patients at the cost of relatively high toxicity. Tumor vaccination has shown great promise in a variety of cancers, particularly in the adjuvant setting. Studies in metastatic setting are suitable to identify the best adjuvants and to optimize vaccination schedules. CpGs are synthetic oligonucleotides that have been shown to have superior immunogenicity in animal and human vaccination studies (Hepatitis B). Besides its positive effect on the specific immune response, CpGs also stimulate the innate immune system. We initiated a phase I/II trial to investigate the potentials of CpG in the treatment of metastatic RCC. Methods: Nephrectomized patients with progressive metastatic RCC were vaccinated with autologous tumor cells (ATC) derived from the primary tumor or metastases. Vaccines consisted of irradiated ATC, PF-3512676 and GM-CSF. The first three induction vaccinations were given weekly followed by subcutaneous administration of IFN-α (6 MIU, TIW) and PF-3512676 (8 mg bi-weekly). After 3 months tumor evaluation was performed and in case of a remission or stable disease patients continued with 3 monthly vaccinations and PF-3512676 /IFN-α. Blood was collected for immunomonitoring and DTH responses against ATC were measured before and after vaccination. Results: Preparation of vaccines was successful in 88% of the patients. Twelve patients were included and treated according to the protocol. Treatment was well tolerated. At the vaccination site we observed erythema and induration. Some patients experienced flu-like symptoms, including fever and fatigue. In all patients we observed only after vaccination a DTH response (&gt; 10 mm) against ATC, suggestive for a specific antitumor response. Three patients (25%) achieved a partial response (durations 6, 4+, 4+ months) and 2 patients (17%) stable disease (3 months). Conclusions: This new combined immunotherapy is tolerable, safe, and immunogenic. Moreover, it can produce tumor responses in advanced RCC. No significant financial relationships to disclose.
TRENDS IN INCIDENCE AND MORTALITY ASSOCIATED WITH ACUTE KIDNEY INJURY IN PATIENTS UNDERGOING PCI FOR ACUTE CORONARY SYNDROME
Authors: Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Roxana Mehran, George Dangas, Jason Kovacic, Pedro Moreno, Birgit Vogel, Sabato Sorrentino, Serdar Farhan, Michela Faggioni, Zhen Ge, Shrema Parikh, Pooja Vijay, Nitin Barman, Vishal Kapur, Samin Sharma, Annapoorna Kini
Journal: Journal of the American College of Cardiology (2017)
Phase II study of ruxolitinib in patients with pStat3+ breast cancer.
Authors: Nancy U. Lin, Rebecca Sue Gelman, Jane E. Brock, Aditya Bardia, Erica L. Mayer, Beth Overmoyer, Vivian Wang, Marie Iannone, Ian E. Krop, Kornelia Polyak, Eric P. Winer
Journal: Journal of Clinical Oncology (2013)

TPS1134 Background: Multiple lines of evidence implicate the IL-6/JAK2/Stat3 signaling pathway in metastatic progression and therapeutic resistance in breast cancer (Marotta et al, JCI2011; Britschgi et al, Cancer Cell 2012). Ruxolitinib, an oral inhibitor of JAK1 and JAK2, is approved for the treatment of intermediate or high-risk myelofibrosis, but has not been extensively tested in solid tumors. Methods: Pts with triple-negative breast cancer or inflammatory breast cancer of any subtype are eligible for prescreening of archival tumor tissue for pStat3 expression by immunohistochemistry. Pts with high (Cohort A; T-score &gt;5) or low (Cohort B; T-score 3-4) pStat3 expression, measurable disease, adequate organ function, ECOG PS 0-2, and progression through &gt; 1 line of prior therapy may proceed to receive ruxolitinib, 25 mg orally twice daily. Staging studies are performed at baseline (BL) and every 8 weeks (wk). Baseline tumor biopsy is required for pts who have accessible disease, with an optional biopsy at progression. Blood for IL-6, CRP, and circulating tumor cells are collected at BL, Wk 4, and off-treatment. Patient reported outcomes including EORTC QLQ C-30 and the M.D. Anderson Symptom Inventory are collected at BL, Wk 4, Wk 8, and off-treatment. Statistical Considerations: The primary endpoint of this open-label phase 2 trial is objective response by RECIST 1.1. The study is designed to distinguish between a response rate of 5% versus 20% in each cohort, separately. If &gt; 2 responses out of 21 pts are observed in the first stage of Cohort A, a further 20 pts will be entered on that cohort; the agent will be deemed worthy of further study if &gt; 5 of the total 41 pts achieve an objective response (power 0.90, type I error 0.046). Cohort B will open to accrual if Cohort A passes the first stage. If &gt; 2 responses out of 21 pts are observed in the first stage of Cohort B, a further 20 patients will be entered into Cohort B, and the agent will be deemed worthy of further study if &gt; 5 of the total 41 pts achieve an objective response (power 0.90, type I error 0.046). Study Status: A total of 85 patients have consented for prescreening of tumor tissue. As of January 3, 2013, 5 of a planned 41 patients with high pStat3 IHC scores have been treated with ruxolitinib, and accrual is ongoing. Clinical trial information: NCT01562873.